2016
DOI: 10.1016/j.jconrel.2015.12.020
|View full text |Cite
|
Sign up to set email alerts
|

Delivery of siRNA targeting tumor metabolism using non-covalent PEGylated chitosan nanoparticles: Identification of an optimal combination of ligand structure, linker and grafting method

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

1
41
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 77 publications
(43 citation statements)
references
References 42 publications
1
41
0
Order By: Relevance
“…Chitosan nanoparticles (NPs) as potential drug delivery carriers have been widely studied in cancer treatment, as well as in the early diagnosis and detection of tumour biomarkers [1][2][3] in vivo and in tumour-targeted therapy [4][5][6][7]. CS as a carrier material is biodegradable, non-toxic and easily prepared when obtaining NPs featuring a suitable particle size, round shape and high dispersibility.…”
Section: Introductionmentioning
confidence: 99%
“…Chitosan nanoparticles (NPs) as potential drug delivery carriers have been widely studied in cancer treatment, as well as in the early diagnosis and detection of tumour biomarkers [1][2][3] in vivo and in tumour-targeted therapy [4][5][6][7]. CS as a carrier material is biodegradable, non-toxic and easily prepared when obtaining NPs featuring a suitable particle size, round shape and high dispersibility.…”
Section: Introductionmentioning
confidence: 99%
“…One suggestion has been that SLC1A5-mediated import of glutamine provides an exchange substrate for the uptake of leucine (18) and other essential amino acids via LAT1, to meet metabolic demands and signal to mTOR (16). Coupled with the discovery that the glutaminolytic switch is promoted by oncogenes and inhibited by tumor suppressors, this has driven the search for SLC1A5 inhibitors (1922). Indeed, blocking of SLC1A5 has been shown to diminish or prevent tumor cell proliferation in different cancers (2328).…”
Section: Introductionmentioning
confidence: 99%
“…6,7 However, a variety of physiological, cellular, and immunological barriers hinder siRNA molecules from reaching their target site. 8 Physiological barriers are composed of endothelial barrier, degradation by nucleases, reticuloendothelial system uptake, etc. siRNA therapeutics also need to overcome various cellular barriers for their intracellular entry, endosomal escape, and effective protein knockdown.…”
Section: Introductionmentioning
confidence: 99%